FIELD: chemistry.
SUBSTANCE: invention relates to 2,5 substituted arylsulphonamides of formula (Ia) or to their pharmaceutically acceptable salts, solvates, hydrates, stereoisomers or tautomers, where X represents S, SO or SO2; Y and Z represents (i) Y represents NR5; and Z represents =O, CO2R6 or C1-6alkyl; or (ii) Y represents CH2, CHF, CHCH3, O, S or SO2; and Z represents hydrogen or C1-6alkyl; R1 and R2 each independently represents halogen, C1-6alkyl or C1-6 halogenalkyl; R3 represents CN or NO2; R4 represents hydrogen or C1-6alkyl; R5 represents hydrogen or C1-6alkyl; and R6 represents hydrogen or C1-6alkyl. Invention also relates to compounds of formula (I) and (II), values of radicals of which are given in the invention formula, specific compounds, pharmaceutical composition based on compound of formula
, 
and
,
method of modulating CCR3 activity.
EFFECT: obtained are novel compounds, possessing useful biological properties.
18 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2,5-DISUBSTITUTED ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2532515C2 |
| NOVEL POLYCYCLIC COMPOUNDS | 2006 |
|
RU2434006C2 |
| ARYLSULPHONAMIDE CCR3 ANTAGONISTS | 2010 |
|
RU2539591C2 |
| NEW SUBSTITUTED 8-HETEROARYLXANTINES AND BASED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2357969C2 |
| DIPEPTIDE DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, METHODS OF THEIR SYNTHESIS, ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION | 1992 |
|
RU2098424C1 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
| NOVEL FLOROGLUCIN DERIVATIVES, POSSESSING ACTIVITY WITH RESPECT TO SELECTIN LIGAND | 2006 |
|
RU2418584C2 |
| DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | 2009 |
|
RU2514937C2 |
| PYRAZINE DERIVATIVES USED AS ATR KINASE INHIBITORS | 2009 |
|
RU2604066C2 |
| INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITORS, PREPARATION AND USE THEREOF | 2015 |
|
RU2719428C2 |
